Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO (THALLO)

This study has been terminated.
(Over the course of this study stem cell transplant was determined to be standard of care for this disease and as such the study is no longer relevant.)
Sponsor:
Collaborator:
Texas Children's Hospital
Information provided by (Responsible Party):
Kathryn Leung, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00578292
First received: December 19, 2007
Last updated: July 20, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2016
  Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)